Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Filgotinib maleate by Alfasigma for Immunoglobulin G4-Related Disease (IgG4-RD): Likelihood of Approval
Filgotinib maleate is under clinical development by Alfasigma and currently in Phase II for Immunoglobulin G4-Related Disease (IgG4-RD). According to...
Filgotinib maleate by Alfasigma for Idiopathic Inflammatory Myopathy (IIM): Likelihood of Approval
Filgotinib maleate is under clinical development by Alfasigma and currently in Phase II for Idiopathic Inflammatory Myopathy (IIM). According to...
Filgotinib maleate by Alfasigma for Behcet Disease: Likelihood of Approval
Filgotinib maleate is under clinical development by Alfasigma and currently in Phase II for Behcet Disease. According to GlobalData, Phase...
Filgotinib maleate by Alfasigma for Polyarticular Juvenile Idiopathic Arthritis (PJIA): Likelihood of Approval
Filgotinib maleate is under clinical development by Alfasigma and currently in Phase I for Polyarticular Juvenile Idiopathic Arthritis (PJIA). According...
Filgotinib maleate by Alfasigma for Giant Lymph Node Hyperplasia (Castleman's Disease): Likelihood of Approval
Filgotinib maleate is under clinical development by Alfasigma and currently in Phase I for Giant Lymph Node Hyperplasia (Castleman's Disease)....
Filgotinib maleate by Galapagos for Giant Lymph Node Hyperplasia (Castleman's Disease): Likelihood of Approval
Filgotinib maleate is under clinical development by Galapagos and currently in Phase I for Giant Lymph Node Hyperplasia (Castleman's Disease)....